Skip to search formSkip to main contentSkip to account menu

lexatumumab

A fully human monoclonal agonistic antibody directed against tumor necrosis factor-alpha (TNF-alpha)-related apoptosis-inducing ligand receptor-2… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2012
Highly Cited
2012
PURPOSE Lexatumumab is an agonistic, fully human monoclonal antibody against tumor necrosis factor-related apoptosis-inducing… 
2012
2012
Background: Rhabdomyosarcomas (RMS) are often resistant to TRAIL-induced apoptosis. Results: IAP inhibitors prime RMS cells to… 
Highly Cited
2010
Highly Cited
2010
BACKGROUND Lexatumumab (HGS-ETR2) is a fully human agonistic mAb to the tumor necrosis factor-related apoptosis-inducing ligand… 
Highly Cited
2010
Highly Cited
2010
Tumor necrosis factor related apoptosis-inducing ligand (TRAIL) and agonistic anti-DR4/TRAIL-R1 and anti-DR5/TRAIL-R2 antibodies… 
Highly Cited
2009
Highly Cited
2009
Mapatumumab and lexatumumab are fully human monoclonal antibodies that bind and activate human tumor necrosis factor-related… 
Highly Cited
2007
Highly Cited
2007
Purpose: To assess the safety and tolerability, pharmacokinetics, and early evidence of antitumor activity of escalating doses of… 
Highly Cited
2007
Highly Cited
2007
BackgroundThe incidence of malignant pleural mesothelioma (MPM) is associated with exposure to asbestos, and projections suggest… 
Highly Cited
2007
Highly Cited
2007
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) preferentially induces apoptosis in malignant cells by binding to… 
Highly Cited
2007
Highly Cited
2007
14006 Background: Lexatumumab (HGS-ETR2) is a fully-human agonistic monoclonal antibody that targets and activates the Tumor…